Results 121 to 130 of about 1,181,836 (211)

‘Communication Is Crucial’: A Qualitative Study of Patient Expectations of Diagnostic Tests in Emergency Medicine Practice

Health Expectations, Volume 29, Issue 2, April 2026.
ABSTRACT Introduction Value‐based diagnostic tests improve patient safety. Understanding patient expectations can enhance the value of diagnostic tests in Emergency Departments. The aim of this study was to explore patient expectations about diagnostic tests to inform diagnostic stewardship in emergency medicine practice. Methods A qualitative study of
Vinay Gangathimmaiah, Rebecca Evans, Tarun Sen Gupta, Karen Cupitt, Sharon Oakley, Karen Carlisle   +5 more
wiley   +1 more source

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

Biologics: Targets & Therapy, 2022
Valeria Dipasquale, Ugo Cucinotta, Claudio Romano Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G.
Dipasquale V, Cucinotta U, Romano C
doaj  

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Therapeutic Advances in Gastroenterology, 2019
Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the
Ágnes Milassin, Anna Fábián, Tamás Molnár   +2 more
doaj   +1 more source

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease [PDF]

, 2017
BACKGROUND: Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, that may have a great role in the therapeutic decisions during maintenance biological therapy. RESEARCH DESIGN AND METHODS: 48 inflammatory bowel disease
Bor Renáta, Bálint Anita, Farkas Klaudia, Fábián Anna, Matuz Mária, Milassin Ágnes, Molnár Tamás, Nagy Ferenc, Rutka Mariann, Szepes Zoltán   +9 more
core   +3 more sources

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Biologics: Targets & Therapy, 2018
Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI,
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I   +6 more
doaj  

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)

Drug Design, Development and Therapy, 2020
Soohyun Kim, 1, 2,* Siun Kim, 1, 2,* Howard Lee 1– 4 1Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; 2Center for Convergence Approaches in Drug Development,
Kim S, Kim S, Lee H
doaj  

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico

Revista de Gastroenterología de México (English Edition), 2018
The biotechnology-derived medicines known as biosimilars are defined as non-originator treatments that have demonstrated quality, efficacy, and safety comparable to the reference biologic drug.
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez, J.K. Yamamoto-Furusho   +9 more
doaj   +1 more source

Kontrollierte Einführung des Infliximab-Biosimilars CT-P13 bei Patienten mit Morbus Crohn und Colitis ulcerosa in einer großen deutschen Zentrumskohorte [PDF]

, 2021
Einleitung: Das Infliximab Biosimilar CT-P13 wurde 2013 von der EMA im Rahmen eines Extrapolationsprozesses für die Behandlung von chronisch entzündlichen Darmerkrankungen (CED) ohne Zulassungsstudien genehmigt.
Röder, Helene
core  

Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México

Revista de Gastroenterología de México, 2018
Resumen: Los medicamentos biotecnológicos biocomparables son definidos como tratamientos no innovadores que han demostrado calidad, eficacia y seguridad comparable al medicamento de referencia.
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez, J.K. Yamamoto-Furusho   +9 more
doaj   +1 more source

Update on therapeutic approaches for rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a common chronic inflammatory and destructive arthropathy that consumes considerable personal, social and economic costs.
Cavaco-Paulo, Artur, Gomes, Andreia, Nogueira, Eugenia, Preto, Ana   +3 more
core   +1 more source